[131I]标记双靶点免疫抑制剂增强抗肿瘤免疫应答
研究建立[131I]标记的KN046(靶向PD-L1和CTLA-4的双特异性单域抗体-Fc融合蛋白)作为新型放射免疫治疗药物,用于治疗恶性黑色素瘤并探索机制。SPECT/CT成像用于识别KN046免疫治疗候选靶点,[18F]-FDG和[68Ga]-NOTA-GZP micro-PET/CT评估体内免疫应答。低剂量[131I]联合KN046增强免疫敏感性显著提高免疫治疗应答率,并上调MHC-I和Fas表达、增加T细胞活化和肿瘤浸润免疫细胞计数。
要点
- [131I]-KN046对PD-L1/CTLA-4具有高亲和力和特异性,体内瘤内滞留能力良好。
- 低剂量[131I]联合KN046增强免疫敏感性,显著提高免疫治疗应答率。
- [131I]-KN046暴露上调MHC-I和Fas表面分子表达,增加T细胞活化程度和肿瘤浸润免疫细胞计数。
核心结论
- 低剂量[131I]联合双靶点免疫抑制剂可用于识别治疗应答者亚群,并展现出增强抗肿瘤免疫应答的巨大潜力。
研究设计与样本
- 研究建立[131I]标记的KN046作为新型放射免疫治疗药物治疗恶性黑色素瘤,并探索其机制。
- 采用静脉注射[131I]-KN046后SPECT/CT成像识别KN046免疫治疗候选靶点。
- 采用[18F]-FDG和[68Ga]-NOTA-GZP(颗粒酶B特异性PET显像剂)micro-PET/CT评估[131I]-KN046治疗后体内免疫应答。
- 通过探索[131I]诱导的肿瘤免疫原性相关抗原释放以及治疗后荷瘤小鼠的组织学和生存情况评估[131I]-KN046的协同治疗效果。
主要发现
- 构建的[131I]-KN046对PD-L1/CTLA-4免疫靶点表现出高亲和力和特异性,并具有优异的体内瘤内滞留能力,从而实现良好的抗肿瘤疗效。
- 低剂量[131I]与KN046增强的免疫敏感性联合显著提高了免疫治疗应答率。
- 肿瘤细胞暴露于[131I]-KN046导致MHC-I和Fas表面分子表达上调,T细胞活化程度和肿瘤浸润免疫细胞计数显著增加。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
UNLABELLED: Radionuclides theranostic are ideal "partners" for bispecific antibodies to explore the immune response of patients and synergistic treatment. A bispecific single-domain antibody-Fc fusion protein, KN046, exhibits a good treatment effect by binding to programmed cell death-ligand 1 (PD-L1) and cytotoxic T-lymphocyte-associated protein 4 (CTLA-4). An ionizing-radiation stimulus mediated by a low-dose of [131I] may be used for immunopotentiation. In this study, we established [131I]-labeled KN046 as a novel radioimmunotherapy agent to treat malignant melanoma and explored the mechanism. METHODS: After intravenous injection of [131I]-KN046, SPECT/CT imaging was applied to identify candidate targets for KN046 immunotherapy. [18F]-FDG and [68 Ga]-NOTA-GZP (granzyme B-specific PET imaging agent) micro-PET/CT imaging was used to assess the immune response in vivo after [131I]-KN046 treatment. The synergistic treatment effect of [131I]-KN046 was evaluated by exploring the [131I]-based radionuclide-induced release of tumor immunogenicity-related antigens as well as the histology and survival of tumor-bearing mice after treatment. RESULTS: The constructed [131I]-KN046 exhibited high affinity and specificity for PD-L1/CTLA-4 immune targets and had excellent in vivo intratumoral retention capability so as to achieve good antitumor efficacy. More importantly, the combination of low-dose [131I] and KN046-enhanced immunosensitivity increased the immunotherapy response rates significantly. Exposure of tumor cells to [131I]-KN046 led to upregulated expression of MHC-I and Fas surface molecules and significant increases in the degree of T-cell activation and counts of tumor-infiltrating immunocytes. CONCLUSION: Use of low-dose [131I] combined with a dual-target immunosuppressant could be exploited to identify the subset of treatment responders but also exhibited great potential for enhancing antitumor immune responses.
引用
- Jiang C, Tian Q, Xu X, et al. Enhanced antitumor immune responses via a new agent [131I]-labeled dual-target immunosuppressant. Eur J Nucl Med Mol Imaging. 2022. PMID: 36242616. doi:10.1007/s00259-022-05986-4
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。